CancerCare endorses and actively promotes state and federal policies which:
- Ensure equal access to high quality, safe, affordable and comprehensive cancer treatment for all Americans
- Monitor and protect against potential discriminatory insurance benefit design and implementation
- Enable a responsible process for moving government-sponsored insurance programs toward patient-centric, quality based treatment and payment plans
- Facilitate shared decision-making in cancer treatment planning that reflects patients’ values and priorities
- Help expedite the development and implementation of survivorship plans for every cancer patient after active treatment
- Fund the rapid development of novel, safe and effective cancer treatment and support therapies
Our Advocacy Activities:
The CancerCare Patient Values Manifesto
Published in 2019, the CancerCare Patient Values Manifesto is based on the premise that people with cancer and their clinical care teams have a fundamental right to relationships rooted in mutual respect, where communication is open and culturally competent, plain language information is exchanged, goals are shared and patients’ priorities are acknowledged throughout the continuum of care. Learn more >>
The CancerCare Patient Values Initiative
Launched in early 2017, this multi-faceted project intends to reframe the national healthcare policy dialogue to include what’s important to patients and their families, and to incorporate patients’ values and priorities into treatment decision-making models. Learn more >>
The CancerCare Patient Access and Engagement Report
Published in May, 2016, reflecting the perspectives of thousands of Americans diagnosed with cancer, the report identifies many needs and concerns that people experience along the continuum of living with and beyond cancer. Learn more >>
Our Policy Activities:
2021
2020
Letter to Administrator Verma re: CMS-5528-IFC, Most Favored Nation (MFN) Model. December 2020
Comment re: proposed rule in the Notice of Benefit and Payment Parameters for 2022. December 2020
Statement on the President’s Executive Orders on Prescription Drug Pricing. July 2020
Letter to President Trump re: Support for the World Health Organization (WHO). July 2020
Letter to Senator Alexander re: Preparing for the Next Pandemic. June 2020
Statement re: Administration policy encourages discrimination in health care. June 2020
Letter to Secretary Azar and Director Severino re: Emergency Triage Plans. May 2020
Letter to Secretary Azar re: COVID-19 Fixes for Cancer Patients. April 2020
2019
Letter to Administrator Verma re: the Oncology Care First model. December 2019
Letter to Representatives DeGette and Upton re: Cures 2.0 effort. December 2019
Letter to Chairman Alexander and Ranking Member Murray re: Lower Health Care Costs Act. June 2019
Letter to FDA Acting Commissioner Sharpless re: naming of biological products. May 2019
Cancer Organizations Comment on Ruling that ACA is Unconstitutional. December 2018
2018
Letter to HHS Secretary Alex Azar re: Step Therapy. September 2018
Letter to FDA Commissioner Gottlieb re: the Biosimilars Action Plan. September 2018
Letter to Honorable Susan Collins re: Cancer Drug Parity Act. September 2018
Interview with Patricia Goldsmith: This is the “Moonstab,” or, maybe, the “Moonshaft." March 2017
Expansion of Association Health Plans Final Rule Statement. June 2018
Letter to Secretary Azar in support of fixing the 340B Drug Pricing Program. June 2018
Letter to Dr. Crosson and Dr. Mathews of the Medicare Payment Advisory Commission (MedPAC). May 2018
Letter to Secretary Azar from The Partnership for Part D Access. April 2018
Cancer Leadership Council comments on Right to Try legislation. March 2018
Letter to Speaker Ryan and Leader Pelosi on Right to Try Act Opposition. March 2018
Cancer Leadership Council comments on Right to Try legislation. February 2018
2017
Cancer Leadership Council comments on Notice of Benefit and Payment Parameters 2019. November 2017
Cancer Leadership Council comments on Innovation Center RFI. November 2017
Letter to the Senate: Vote no on the Graham-Cassidy healthcare bill. September 2017
Statement to express opposition to American Health Care Act. May 2017
Letter to Congress urging protection of the Johnson Amendment
Letter to Secretary Price on proposed rule on health care market stabilization. March 2017